RBM38 and hepatocellular carcinoma: Activation of RBM38 significantly reverses the resistance of HCC cells to sorafenib by restoring the expression of the lncRNA GAS5, indicating that the RBM38–GAS5 signaling pathway is involved in sorafenib resistance.